GenSight Readying to Ask EMA to Approve Gene Therapy for LHON

Print Friendly, PDF & Email

GenSight Biologics announced it has finished a pre-submission meeting with the European Medicines Agency (EMA), a key step in filing a request for the approval of Lumevoq , its gene therapy for Leber hereditary optic neuropathy (LHON). The company expects to file the request, called a marketing authorization application […]